Volition's goal is to make its non-invasive cancer blood tests as common and simple to use as existing diabetic and cholesterol tests on similar formats.
Print E-mail


Volition is developing two types of tests based on the Nucleosomics® technology:

  • Cancer screening tests: tests given to an entire population (e.g. all 50-year-olds). Commonly-given cancer screening tests include colonoscopies for colorectal cancer and Pap smear tests for cervical cancer
  • Cancer diagnostic tests: tests given to a patient when they present at a doctor’s clinic, hospital, or surgical center with cancer-like symptoms. Common cancer diagnostic tests include scans and biopsies Volition has developed a range of around twenty individual assays, each of which identifies and quantifies a particular nucleosome structure.

A panel of assays, encompassing the 4-5 best assays for identifying a particular cancer, will be selected, to make up a single cancer test. Taken as a whole, the test will be able to identify whether the patient has that specific cancer. The test panel will be administered to patients as a single test: they will only need to have one small blood sample drawn. Volition is currently optimizing the individual panels for each cancer, as we continue to discover methods of detecting further nucleosome structures.

Volition’s Nucleosomics tests are protected by worldwide patent applications filed initially in Europe and the United States of America.

A range of NuQ® immunoassays for the analysis of nucleosome structures is available for purchase by research institutions at www.nucleosomics.com.


Copyright © 2011 VolitionRX. All Rights Reserved
VolitionRx - Singapore - 1 Scotts Road - #24-05 Shaw Centre - Singapore 228208
VolitionRx - Belgium - Centre Technologique - Rue du Séminaire, 20A - B-5000 Namur - Belgium